# Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

> **NCT00334438** · PHASE1 · COMPLETED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 12 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** bortezomib
- **RADIATION:** yttrium Y 90 ibritumomab tiuxetan
- **RADIATION:** Indium 111 ibritumomab tiuxetan

## Key facts

- **NCT ID:** NCT00334438
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2008-10
- **Final completion:** 2011-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-12-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00334438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00334438, "Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-09-12 from https://api.ai-analytics.org/clinical/NCT00334438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*